Cargando…
Phenome-based gene discovery provides information about Parkinson’s disease drug targets
BACKGROUND: Parkinson disease (PD) is a severe neurodegenerative disease without curative drugs. The highly complex and heterogeneous disease mechanisms are still unclear. Detecting novel PD associated genes not only contributes in revealing the disease pathogenesis, but also facilitates discovering...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009520/ https://www.ncbi.nlm.nih.gov/pubmed/27586503 http://dx.doi.org/10.1186/s12864-016-2820-1 |
_version_ | 1782451527390068736 |
---|---|
author | Chen, Yang Xu, Rong |
author_facet | Chen, Yang Xu, Rong |
author_sort | Chen, Yang |
collection | PubMed |
description | BACKGROUND: Parkinson disease (PD) is a severe neurodegenerative disease without curative drugs. The highly complex and heterogeneous disease mechanisms are still unclear. Detecting novel PD associated genes not only contributes in revealing the disease pathogenesis, but also facilitates discovering new targets for drugs. METHODS: We propose a phenome-based gene prediction strategy to identify disease-associated genes for PD. We integrated multiple disease phenotype networks, a gene functional relationship network, and known PD genes to predict novel candidate genes. Then we investigated the translational potential of the predicted genes in drug discovery. RESULTS: In a cross validation analysis, the average rank for 15 known PD genes is within top 0.8 %. We also tested the algorithm with an independent validation set of 669 PD-associated genes detected by genome-wide association studies. The top ranked genes predicted by our approach are enriched for these validation genes. In addition, our approach prioritized the target genes for FDA-approved PD drugs and the drugs that have been tested for PD in clinical trials. Pathway analysis shows that the prioritized drug target genes are closely associated with PD pathogenesis. The result provides empirical evidence that our computational gene prediction approach identifies novel candidate genes for PD, and has the potential to lead to rapid drug discovery. |
format | Online Article Text |
id | pubmed-5009520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50095202016-09-08 Phenome-based gene discovery provides information about Parkinson’s disease drug targets Chen, Yang Xu, Rong BMC Genomics Research BACKGROUND: Parkinson disease (PD) is a severe neurodegenerative disease without curative drugs. The highly complex and heterogeneous disease mechanisms are still unclear. Detecting novel PD associated genes not only contributes in revealing the disease pathogenesis, but also facilitates discovering new targets for drugs. METHODS: We propose a phenome-based gene prediction strategy to identify disease-associated genes for PD. We integrated multiple disease phenotype networks, a gene functional relationship network, and known PD genes to predict novel candidate genes. Then we investigated the translational potential of the predicted genes in drug discovery. RESULTS: In a cross validation analysis, the average rank for 15 known PD genes is within top 0.8 %. We also tested the algorithm with an independent validation set of 669 PD-associated genes detected by genome-wide association studies. The top ranked genes predicted by our approach are enriched for these validation genes. In addition, our approach prioritized the target genes for FDA-approved PD drugs and the drugs that have been tested for PD in clinical trials. Pathway analysis shows that the prioritized drug target genes are closely associated with PD pathogenesis. The result provides empirical evidence that our computational gene prediction approach identifies novel candidate genes for PD, and has the potential to lead to rapid drug discovery. BioMed Central 2016-08-31 /pmc/articles/PMC5009520/ /pubmed/27586503 http://dx.doi.org/10.1186/s12864-016-2820-1 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Chen, Yang Xu, Rong Phenome-based gene discovery provides information about Parkinson’s disease drug targets |
title | Phenome-based gene discovery provides information about Parkinson’s disease drug targets |
title_full | Phenome-based gene discovery provides information about Parkinson’s disease drug targets |
title_fullStr | Phenome-based gene discovery provides information about Parkinson’s disease drug targets |
title_full_unstemmed | Phenome-based gene discovery provides information about Parkinson’s disease drug targets |
title_short | Phenome-based gene discovery provides information about Parkinson’s disease drug targets |
title_sort | phenome-based gene discovery provides information about parkinson’s disease drug targets |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009520/ https://www.ncbi.nlm.nih.gov/pubmed/27586503 http://dx.doi.org/10.1186/s12864-016-2820-1 |
work_keys_str_mv | AT chenyang phenomebasedgenediscoveryprovidesinformationaboutparkinsonsdiseasedrugtargets AT xurong phenomebasedgenediscoveryprovidesinformationaboutparkinsonsdiseasedrugtargets |